binge eating disorder

Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. (OTCQB: TRYPF) shared the interim results for the first five patients dosed in its Phase 2 STOP (Study of the Treatment of Overeating utilizing Psilocybin) trial.  The STOP trial, done in collaboration with the University of Florida,...

Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding psilocybin-based TRP-8803 development’s IP.   Tryp's Psilocybin-For-...

Psilocybin, the active ingredient in “magic mushrooms,” could be part of the solution for people struggling with binge eating disorder, a condition characterized by recurring episodes of eating large quantities of food and feeling unable to stop. Tryp Therapeutics, Inc. (OTCQB: TRYPF),...